U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

i

Development of a Humanized Antibody with High Therapeutic Potential against Dengue Virus Type 2

Supporting Files Public Domain
File Language:
English


Details

  • Alternative Title:
    PLoS Negl Trop Dis
  • Personal Author:
  • Description:
    Background ; Dengue virus (DENV) is a significant public health threat in tropical and subtropical regions of the world. A therapeutic antibody against the viral envelope (E) protein represents a promising immunotherapy for disease control. ; Methodology/Principal Findings ; We generated seventeen novel mouse monoclonal antibodies (mAbs) with high reactivity against E protein of dengue virus type 2 (DENV-2). The mAbs were further dissected using recombinant E protein domain I-II (E-DI-II) and III (E-DIII) of DENV-2. Using plaque reduction neutralization test (PRNT) and mouse protection assay with lethal doses of DENV-2, we identified four serotype-specific mAbs that had high neutralizing activity against DENV-2 infection. Of the four, E-DIII targeting mAb DB32-6 was the strongest neutralizing mAb against diverse DENV-2 strains. Using phage display and virus-like particles (VLPs) we found that residue K310 in the E-DIII A-strand was key to mAb DB32-6 binding E-DIII. We successfully converted DB32-6 to a humanized version that retained potency for the neutralization of DENV-2 and did not enhance the viral infection. The DB32-6 showed therapeutic efficacy against mortality induced by different strains of DENV-2 in two mouse models even in post-exposure trials. ; Conclusions/Significance ; We used novel epitope mapping strategies, by combining phage display with VLPs, to identify the important A-strand epitopes with strong neutralizing activity. This study introduced potential therapeutic antibodies that might be capable of providing broad protection against diverse DENV-2 infections without enhancing activity in humans.
  • Subjects:
  • Source:
    PLoS Negl Trop Dis. 2012; 6(5).
  • Document Type:
  • Volume:
    6
  • Issue:
    5
  • Download URL:
  • File Type:
    Filetype[PDF - 2.31 MB]
  • Collection(s):
  • Main Document Checksum:
    urn:sha256:7c0bf6eaea168c419e8731547bff0fd4c6042d2519b2570dc9f4d36121035e50
File Language:
English
ON THIS PAGE
 Was this page helpful?
 Found an issue?
Send us an email at:
CDC STACKS serves as an archival repository of CDC-published products including scientific findings, journal articles, guidelines, recommendations, or other public health information authored or co-authored by CDC or funded partners.

As a repository, CDC STACKS retains documents in their original published format to ensure public access to scientific information.